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ABSTRACT 
Risk factors for arterial ischaemic stroke in children include vasculopathy and prothrombotic 
risk factors but their relative importance to recurrent stroke is uncertain. Data on recurrent 
stroke from the databases held in Canada (Toronto), Germany (Kiel-Lübeck/Münster), and 
UK (London/Southampton) were pooled. Data were available from 894 patients aged 1 
month to 18 years at first stroke (median age 6 years) with a median follow-up of 35 months. 
160/894 patients (17.9%) had recurrence from 1 day to 136 months after first stroke (median 
3.1 months). Among 288 children with vasculopathy, recurrence was significantly more 
common (hazard ratio (HR) 2.5, 95% confidence intervals (CI) 1.92-3.5) compared to 
children without vasculopathy. Adjusting for vasculopathy, isolated antithrombin deficiency 
(HR 3.9; 95%CI 1.4-10.9), isolated elevated lipoprotein (a) (HR 2.3; 95%CI 1.3-4.1), and the 
presence of more than one prothrombotic risk (HR 1.9; 95%CI 1.12-3.2) were independently 
associated with an increased risk of recurrence. Recurrence rates calculated per 100 
person-years were 10 (95%CI 3-24) for antithrombin deficiency, 6 (95%CI 4-9) for elevated 
lipoprotein (a), and 13 (95%CI 7-20) for the presence of more than one prothrombotic risk. 
Identifying children at increased for second stroke events is important in intensifying 
measures aimed at preventing recurrent stroke.  
WC: 2688   
Abstract: 199 
Main Text: 2630, 3 Figures, 3 Tables, 1 supplemental Figure 
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Introduction 
Published estimates of arterial ischaemic stroke (AIS) incidence in children range from 1.2 to 
8 per 100,000 children annually.1-5 Prior diagnoses in children with symptomatic AIS are 
multiple and include cardiac disorders, haematological conditions (sickle cell anaemia, 
prothrombotic disorders), collagen tissue diseases, metabolic disorders, other chronic 
diseases, and acute illnesses.6-8 Childhood infections, including Varicella Zoster virus, have 
been shown to be associated with an increased risk of AIS, with routine vaccinations being 
protective against AIS.9,10 In addition, the presence of prothrombotic risk factors has been 
found in small case series and case control studies to be associated with ischaemic stroke 
in children, with this association confirmed by meta-analysis.11 This is in contrast to perinatal 
stroke, in which recent studies have not shown an association with thrombophilia12 and 
recurrence is relatively rare.13,14 
 
In children, stroke recurrence is common and associated with significant morbidity and 
mortality. Five-year recurrence rates are estimated to be between 6-20%, with rates as high 
as 66% in certain subgroups.15-20 Several of these studies have identified vasculopathy, in 
particular moyamoya, as an important factor in predicting recurrent stroke.8,15,20 There are 
some early data to suggest that prothrombotic states may also enhance the risk of 
recurrence, but many of these studies are limited by size and scope.7,11,15,16,21 We therefore 
investigated in an international cohort study the relevance of prothrombotic risk factors, as 
well as underlying stroke subtypes, to a second stroke in paediatric patients.  
 
Methods 
Study population, study design, and study endpoints: The present study is a multicenter 
cohort study to assess the rate of symptomatic stroke recurrence per 100 person-years 
following a first onset of AIS. The core protocol was developed by the German collaborative 
group and was adopted by centres in Toronto and the UK; data were pooled across these 
sites to determine whether the data were generalizable and to increase power for the 
secondary study objective, i.e. the time to recurrence. From January 1990 to January 2016, 
consecutively admitted in- and outpatients from each study site, i.e. Canada (Toronto: single 
center registry), Germany (Kiel-Lübeck/Münster: multi-center national registry: patients newly 
enrolled after 2002), and UK (London/Southampton: 2-centre registry) were enrolled and 
pooled into the paediatric stroke database located in Germany. Consecutive patients with 
first symptomatic AIS were recruited whether or not prothrombotic risk factors were present 
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and recurrence was ascertained at follow-up in survivors. Patients referred from other tertiary 
centres were excluded. Neonates < 1 month of age and children with sickle cell anaemia 
were not enrolled in the present dataset, as recurrence rates and risk factors differ markedly 
from other sub-types of childhood AIS. After enrolment, children with moyamoya, and those 
with congenital homozygous protein C or antithrombin deficiency, were excluded, since 
recurrence risk and therapy differ substantially from the remaining study cohort. In addition, 
we excluded children in whom thrombophilia screening was not performed and those lost to 
follow-up. 
First AIS was confirmed by standard imaging methods, i.e. magnetic resonance imaging 
(MRI) and computerized tomography (CT).15,16 AIS was defined as acute onset neurological 
deficit with an acute focal infarct in a corresponding arterial vascular territory.  
Recurrence was defined as clinically symptomatic AIS events presenting with acute focal 
neurologic deficits with infarction in a vascular distribution on neuroimaging and beginning 
more than 24 hours following the first stroke onset. Fixed study end date for last follow-up 
was January 1, 2017. The number of patients with recurrence, and type of antithrombotic 
(antiplatelet or anticoagulant) therapy administered prior to recurrence were noted. The 
proportion of deaths following stroke recurrence was also noted. Following discontinuation of 
antithrombotic treatment, asymptomatic paediatric patients were followed-up every few 
months for the first year and at more prolonged intervals thereafter (at least yearly). All 
patients were seen at least once for a follow-up with a paediatric neurologist. Transient 
ischaemic attacks (TIAs), defined as acute onset neurological deficit lasting < 24 hours and 
with no associated infarct on repeat neuroimaging, were excluded from the study endpoint, 
as were ‘silent’ recurrent strokes noted on follow-up imaging without clinical manifestations.   
Ethics: This study was performed in accordance with the ethical standards laid down in the 
updated version of the 1964 Declaration of Helsinki and was either approved or the 
requirement for approval was waived, by Research Ethics Boards at the Hospital for Sick 
Children, Toronto, the Great Ormond Street Hospital, (and UK National Health Service), and 
University of Münster respectively. 
 
In the online supplement, details of stroke subtypes,11,22 treatment modalities,21-25 laboratory 
work-up26-28 and statistical methods applied29,30 are summarized.   
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Results 
From January 1990 to January 2016, a total of 990 in- and outpatients consecutively 
reviewed at the study sites from Canada (n=308), Germany (n=461), and UK (n=221) aged 
>1 month and without sickle cell anaemia were enrolled and pooled into the paediatric stroke 
database located in Germany. After enrolment, we excluded 54 children with moyamoya, two 
patients with either congenital homozygous protein C or homozygous antithrombin 
deficiency, 5 children lost to follow-up and 35 children in whom thrombophilia screening was 
not performed (figure 1). We studied 894 consecutively recruited children aged 1 month to < 
18 years who survived a first episode of AIS (figure 1, table 1) and were followed for median 
(minimum-maximum) duration of 35 (1-256) months. Clinical characteristics are summarized 
in table 1. In total, 160 children (17.9%) experienced a recurrent AIS event at a median 
interval from initial stroke of 3.1 months (min-max: 0.1-136). Death at the time of the second 
AIS occurred in 15 of 160 children (9.4%). The overall recurrence rate calculated per 100 
person-years was 5 (95%CI: 4-6) with a yearly incidence of 0.05%.  
Data on antithrombotic prophylaxis prior to a second AIS, i.e. anticoagulation with LMWH or 
vitamin-K antagonists (VKA) or antiplatelet (ASA or clopidogrel) therapy, were available in a 
subgroup of 122 out of 160 cases on an exploratory basis: antithrombotic prophylaxis was 
administered independent of the presence or absence of thrombophilia (p=0.89) or different 
stroke subtypes (p=0.2). In children with vasculopathy prior to the second AIS, 34 of 72 index 
patients were on antiplatelet agents (ASA alone) and 19 were treated with LMWH, one child 
developed a second stroke whilst taking VKA. In patients without vasculopathy 15 out of 50 
children were on ASA, twice combined with Clopidogrel, seven received LMWH and three 
were on oral anticoagulation with VKA. 44 of the 122 patients did not receive anticoagulation 
or antiplatelet therapy prior to a second AIS (vasculopathy group n=19; non-vasculopathy 
children n=25; p=0.05). 
Vascular territory of second AIS: In the majority of cases (75%) the same vascular territory 
was involved as in the first AIS. The anterior circulation was involved in 62.5% and the 
posterior circulation in 37.5%.  
Stroke subtypes (table 1): Stroke subtypes are depicted in figure 1 and table 1. 32.2% of 
paediatric stroke patients (n=288) had vasculopathy. Sub-classification of vascular stroke is 
shown in the online supplement. Imaging confirmed recurrence rates occurred in 160/880 
enrolled children, for i) cardiac disease 23/109 (21.1%) ii) vasculopathy 82/284 (28.9%), for 
iii) cryptogenic 41/401 (10.2%) and for iv) other stroke types 14/78 (17.9%). Recurrent AIS 
was significantly more frequent in patients with vasculopathy (HR 2.5, 95% CI 1.92-3.5; p< 
0.001) compared to patients with cryptogenic stroke. Calculated per 100 person-years in 
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those with vasculopathy, the recurrence rate was 8 (95% CI: 6-10) with a yearly incidence 
rate of 7.7%. The time to recurrence, calculated as the probability of AIS-free survival, 
comparing paediatric AIS patients with and without vasculopathy, is depicted in figure 2 (log 
rank p-value < 0.001). No statistically significant association between recurrent AIS and the 
remaining stroke subgroups was found: cardiac stroke (HR 1.15; 95% CI 0.7-2.0; p=0.61); 
non-vascular/non-cardiac/non-idiopathic (HR 1.01; 95% CI 0.5-2.0; p=0.95).   
Prothrombotic risk factors (table 2): Results derived from univariable analysis are depicted in 
table 2. A single prothrombotic disorder was detected in 269 children, whereas more than 
one prothrombotic risk factor was diagnosed in 88 cases. Heterozygous antithrombin 
deficiency, high lipoprotein (a), high fibrinogen, high fasting homocysteine and the presence 
of more than one prothrombotic disorder were associated with recurrence. Of the 7/23 
patients with heterozygous antithrombin deficiency who experienced recurrent stroke, 
none were on unfractionated heparin or VKA: four were prescribed ASA at the time of 
recurrence, one patient was on LMWH, while 2 subjects were taking no prophylaxis 
immediately prior to re-stroke (non-compliance was not excluded). In six of 23 (26%)  
patients with combined defects and a second stroke, the factor 5 mutation at rs6025 was 
involved. Interestingly, however, the mutation at factor 2 at rs1799963 did not play a role in 
children with combined defects.  
Examination of the roles of i) different stroke subtypes and ii) prothrombotic risk factors using 
multivariable Cox proportional hazards regression of variables with a p-value < 0.15 in 
univariable analysis, adjusted for age, gender and study centre, demonstrated that the 
presence of vasculopathy (HR 2.5), antithrombin deficiency (HR 3.9), elevated Lp(a) (HR 
2.3) and the presence of more than one prothrombotic risk factor (HR 1.9) were 
independently associated with an increased risk of recurrent stroke (table 3). The time to 
recurrence, i.e. recurrence-free survival comparing children with elevated Lp(a) with 
paediatric AIS patients with normal Lp(a) levels are depicted in figure 3 (log rank p-value < 
0.039). Recurrence rates calculated per 100 person-years were 10 (95%CI: 3-24) for 
antithrombin deficiency (yearly incidence rate 0.1%), 6 (95%CI 4-9) calculated for elevated 
Lp(a) (yearly incidence rate 0.13%), and 13 (95%CI 7-20) for the presence of more than one 
prothrombotic risk factor (yearly incidence rate 0.13%). In the online supplement Kaplan 
Meier survival curves are depicted for children with multiple thrombophilias compared with 
normal thrombophilia status (figure 1 online material).  
Based on its distribution in the Caucasian paediatric population, the number-needed-to-
screen (NNS) to detect one patient with elevated Lp(a) was 10 and to detect children with 
more than one prothrombotic abnormality was 20. 
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Discussion 
In our study cohort of 894 Canadian, English and German paediatric stroke patients >1 
month of age, a second AIS event was diagnosed in 17.9% of patients within a median 
period of 3.1 months after the first stroke onset. Here we have shown, in an international 
cohort of children with paediatric stroke, that the presence of more than one prothrombotic 
risk factor is associated with AIS recurrence in children. Specifically, as demonstrated 
recently in children with recurrent deep venous thrombosis and thromboembolic stroke, 
heterozygous antithrombin deficiency is a major risk factor for second AIS events.31 In 
addition, data presented here confirm an increased risk for recurrent stroke events in the 
subgroup of patients with underlying vasculopathy.15,22,32-35 
The rates of recurrent cerebral thrombo-embolic events vary widely across published 
studies. Differences likely relate to i) the variable inclusion of neonates, known to have a 
very low rate of recurrence, ii) the ethnicity of patients enrolled and other variables in patient 
population iii) the definitions of recurrence and iv) the duration of follow-up. Some studies 
have mixed TIA and recurrent stroke in reporting the recurrence risk.14-20 Adverse outcomes 
resulting from recurrent AIS are certainly more ominous than for TIA alone, with a mortality 
rate after second AIS of 9.4% in our patients. Keeping in mind differences in patient 
populations, underlying diseases as well as treatment modalities applied, and assuming that 
inclusion of TIAs would approximately double the recurrence risk,16 the recurrence rate 
reported by us for AIS alone is within the lower rate of approximately 20% reported by other 
authors.14-20 It is possible that our lower rate of recurrence reflects the use of standardized 
treatment protocols and institutional paediatric Stroke programs at our centres. Specialized 
stroke care is likely to lower the rate of recurrence through experienced selection of patients 
for antiplatelet/anticoagulant treatment and more consistent use of any preventative 
treatment.  
With respect to the inherited prothrombotic risk factors investigated, multivariable analysis 
provides evidence that presence of vasculopathy, heterozygous antithrombin deficiency, 
increased Lp(a) and the presence of more than one thrombophilia are risk factors for 
recurrent ischaemic stroke in paediatric patients.14,36-38 The numbers needed to screen to 
detect one patient each with elevated Lp(a) or combined thrombophilic abnormalities in the 
present cohort were 10 and 20 respectively. The benefit of recognising a thrombophilic 
underlying condition, as well as the NNS to detect a carrier at risk, should be balanced 
against clinical impact, cost and potential insurance implications. In contrast to the literature 
on recurrent venous thromboembolism in a similar population of children, as well as an 
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association with first AIS onset,11,38 the presence of isolated mutations in factor 5 at rs6025, 
factor 2 at rs1799963, protein C- and protein S were not individually significantly associated 
with recurrent arterial ischaemic stroke in this multicenter cohort. Despite the recurrence rate 
of 17.9% comprising 160/894 patients, our study may have been underpowered to find these 
associations. Alternatively, these factors may have been more aggressively treated with 
antithrombotic treatment, reducing the risk of recurrence in affected patients. Importantly, 
combinations of prothrombotic risk factors, including the mutation at factor 5 at rs6025, in 
26% of cases are associated with recurrence, emphasizing the importance of 
comprehensive investigation and appropriate management. 
Our study has several limitations. First, the long duration of the study means that many 
children were enrolled more than a decade ago, when treatments may have been selected 
differently than is currently recommended. While this long duration provided us with the 
opportunity to monitor children for longer-term recurrent AIS, our inclusion of some children 
with only a brief follow-up duration, as short as one month, could also have resulted in our 
underestimating recurrence risk, and our rate of recurrence should therefore be viewed as a 
minimum estimate. Secondly, the proportion of children with vascular, cardiac and 
cryptogenic stroke varied across countries, likely representing either differences in 
assignment of patients to categories (e.g. inclusion or exclusion of occlusion alone as 
‘vasculopathy’) or different referral patterns to the three Toronto, London/Southampton and 
Kiel-Lübeck/Münster centres. Thirdly, we were unable to include paediatric stroke drug 
therapy as a main focus of this study since antithrombotic and antiplatelet agents 
recommended for children with stroke derived from non-randomized paediatric trials and 
small case series are based on a low evidence level, without adjustment for treatable 
prothrombotic risk factors such as heterozygous antithrombin deficiency21-25 or routine drug 
monitoring to detect ASA resistance or non-drug compliance. Finally, the thrombophilia 
testing was done over time and in 3 different laboratory settings. However, since laboratory 
parameters were investigated with standard laboratory techniques and assays and were only 
classified as abnormal when i) abnormal on repeat and ii) confirmed by family studies or the 
identification of an underlying gene mutation,26-28 it likely that our results are reliable.  
In summary, recurrent AIS is relatively frequent, and is associated with significant mortality. 
Risk is enhanced in children who have vasculopathy, even when moyamoya is excluded, 
and in those with certain isolated PRs or more than one prothrombotic disorder is found. The 
study results emphasize the value of pooling individual patient data across geographic 
regions. Future studies should seek to validate our findings in additional patient cohorts of 
children with a first onset of AIS with stroke subtypes clearly defined according to new 
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paediatric stroke classifications like CASCADE.39,40 Of note, our finding that recurrence of 
childhood AIS is comparable across European and North American centres supports the 
feasibility of multi-national recruitment strategies to sufficiently power randomized treatment 
studies, which could include the development of stroke recurrence prediction models. Such 
studies should be focused on prevention of recurrent stroke in sub-populations of paediatric 
patients with the highest risks for recurrent AIS. In addition, from the data reported here, 
prediction models could be derived combining non-moyamoya vasculopathy with the 
presence of multiple thrombophilic risk factors of interest. On the background of regional 
differences with respect to prevalence rates of thrombophilic risk factors across study 
populations, NNS to detect carriers at risk will allow investigators to adequately power future 
paediatric stroke trials. It is important to keep in mind, however, that i) antithrombotic and/or 
antiplatelet therapy may also have a significant impact on the risk of AIS recurrence in 
children, and ii)  up to now, due to the lack of randomized controlled trials, paediatric stroke 
treatment modalities are recommended on a low evidence base;21-25 further efforts must be 
undertaken to also address the latter issue.  
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Table 1: Clinical characteristics of 894 children with first AIS studied for AIS recurrence 
Characteristics Canada  
Number [%] 
Germany  
Number [%] 
UK 
Number [%] 
Total 
Number [%] 
Population at first stroke onset 
• Caucasian 
• Black 
• Asian 
• First Nations/Aboriginal 
• Central/South American 
• Mixed ethnicity 
• Unknown 
 294 [100.0] 
 166   [56.5] 
   17   [05.8] 
   44   [15.0] 
    2    [0.70] 
    5    [01.7] 
    9    [03.1] 
   51   [17.3] 
379 [100.0] 
377 [99.5] 
- 
- 
- 
- 
    2 [0.95] 
221 [100.0] 
190  [86.0] 
    4  [2.0] 
  27  [12.2] 
- 
- 
- 
894 [100.0] 
733  [81.2] 
Median age, years (min-max) 4.8 (0.1-17.7) 7.1 (0.2 -18) 4.5 (0.1-16.7) 6 (0.1-21) 
Male 183 [59.4] 203 [54.7] 125 [56.5] 511 [56.8] 
Proportion of children with a first 
 Cryptogenic AIS 
43 [14.6] 264 [69.5] 96 [43.4] 403 [45.1] 
Proportion of children with a first 
vascular stroke 
89 [30.3] 86 [22.7]  113 [51.1] 288 [32.2] 
Proportion of children with a first 
cardiac stroke 
92 [31.3] 8 [2.1] 9 [4.1] 109 [12.2] 
 
Proportion of children with a  
recurrent AIS 
76 [25.9] 27 [7.1] 57 [25.8] 160 [17.9] 
Proportion of patients on treatment 
prior to second AIS  
54 [71.1] 
 
 
17 [63.0] # 
 
 
30 [52.6] 
 
 
101 [63.1] 
 
 
# Cohort data previously published in part (ref. 25) 
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Table 2: Univariable analysis: association between prothrombotic risk factors and a second 
stroke. A single prothrombotic disorder was detected in 269 children 
Risk Factor  AIS first onset: 
Numbers with 
abnormal test 
/numbers tested [%] 
AIS recurrence:  
Numbers with 
abnormal test 
/numbers tested [%] 
 Chi-
squared  
p-value 
Reference: no thrombophilia 
 
Fasting Lp(a) > 30 
mg/dl  
115/580 [19.8] 23/115 [20.0] 0.04 
Fibrinogen    43/787 [5.5] 13/43 [30.2] 0.04 
Fasting 
homocysteine 
  16/708 [2.3]   7/16 [43.8] 0.01 
Antithrombin-
deficiency 
  23/750 [3.1]   7/23 [30.4] 0.15 
Protein C deficiency   26/778 [3.3]   5/26 [19.2] 0.9 
Protein S deficiency   28/708 [4.0]   7/28 [28.0] 0.2 
Factor 5 at rs6025   71/726 [9.8]   8/71 [11.3] 0.17 
Factor 2 at 
rs1799963 
  21/631 [3.3]   3/21 [15.0] 0.84 
 
Combined defects  88/848 [10.4] 23/88 [26.1] 0.04 
 
Abbreviations used: F: factor; Lp: Lipoprotein 
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 Table 3: Risk contribution to second AIS adjusted for age at onset, gender and study center 
(Cox proportional hazards model) 
 
Risk Factor Hazard 
Ratio 
95% 
Confidence 
Interval  
Stroke subtypes 
Reference: cryptogenic stroke 
Vascular stroke 2.5 1.92-3.5 
Cardiac Stroke 1.15  0.7-2.0 
non-vascular 
/non-cardiac 
/non-cryptogenic 
1.01  0.5-2.0 
Thrombophilia  
Reference: no thrombophilia 
Fasting Lp(a) > 30 mg/dl 2.3 1.3-4.1 
Fibrinogen 0.9 0.3-2.8 
Fasting homocysteine 3.6 0.8-15.8 
Heterozygous Antithrombin-
deficiency 
3.9 1.4-10.9 
Protein C-deficiency 1.3 0.3-5.5 
Protein S deficiency 2.2 0.5-9.8 
Factor 5 at rs6025 0.7 0.23-1.91 
Factor 2 at rs1799963 1.8 0.4-7.8 
 
Combined prothrombotic risk factors 1.9 1.12-3.2 
 
Abbreviations used: F: factor; Lp: Lipoprotein 
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Figure 1: Patient flow chart  
 
Figure 2 demonstrates the AIS-free survival in children with vasculopathy compared with the 
remainder with a normal arterial examination (p< 0.001). 
 
Figure 3 demonstrates the AIS-free survival in children with elevated lipoprotein (a) 
compared with the remainder with normal lipoprotein (a) levels (p= 0.039).  
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Methods 
Stroke Subtypes: Stroke subtypes in the enrolled children were reclassified according to 
explicit predefined criteria based on the TOAST criteria modified for children in which 
“vasculopathy” is substituted for “large vessel atherosclerosis”.11,22 Based on this 
classification in association with underlying diseases/co-morbidities, clinical data and the 
results of diagnostic studies including MR angiography, conventional angiography and 
Doppler ultrasonography, transthoracic and transesophageal echocardiography (ECHO) with 
saline contrast, and electrocardiography, the study patients were classified into four 
subgroups: (i) cardiac disease including persistent foramen ovale and mitral valve prolapse 
detected on ECHO as well as pre-diagnosed congenital heart disease (CHD)  (ii) 
vasculopathy including dissection and other stenosis, e.g. focal cerebral and post-Varicella 
arteriopathy, post radiation and Down syndrome (iii) cryptogenic stroke, with no underlying 
disease/co-morbidities and no vasculopathy, and (iv) non-cardiac, non-vasculopathy and 
non-cryptogenic AIS, including stroke associated with other underlying diseases/co-
morbidities such as systemic viral or bacterial infections including meningitis, post-
vaccination, haemolytic-uraemic syndrome, malignancy or autoimmune disorders and others. 
Patients with both cardiac disease and vasculopathy were classified into the vasculopathy 
group. Ethnicity, age, gender and the proportion of stroke subtypes were collected.  
Classification  of vascular stroke type are as follows: vasculitis including post-Varicella 
vasculitis (n=72), dissection (n=46), transient cerebral arteriopathy (n=7), other specified 
vasculopathy (n=9: brain tumour n=1; post radiation n=2; Down syndrome n=3; catheter 
occlusion n=1; vasospasm n=2) and other unspecified vasculopathy including  intracranial 
large vessel stenosis (n=76), short vessel stenosis with persistent transcranial Doppler-
documented turbulence (n=24), large vessel occlusion (n=37) and hypoplastic arteries of un- 
known origin (n=17). 
Antithrombotic treatment following first symptomatic stroke: At the discretion of the 
participating study centres, paediatric patients with a first stroke onset received 
antithrombotic therapy unless contraindicated by initial haemorrhagic infarction or other risk 
factors for haemorrhage.21-25 
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Laboratory analyses: With written or oral parental consent, the mutations in factor 5 at 
rs6025 and factor 2 at rs1799963 (retrospective genotyping in children with stroke diagnosed 
prior 1995 [factor 5] - & 1997 [factor 2]), as well as circulating levels of lipoprotein (Lp) (a), 
fibrinogen, factor VIIIC, homocysteine, protein C, protein S, and antithrombin were 
investigated with standard laboratory techniques at stroke onset and/or repeated during 
routine follow up visits. To rule out possible laboratory pitfalls induced by the acute stroke 
onset, for example consumption of antithrombin, protein C or protein S or acute phase-
induced elevation of fibrinogen, factor VIII or homocysteine, repeated laboratory 
thrombophilia work-up was performed at least three months after the acute stroke event and 
was repeated if abnormal.11 A non-homozygous type I deficiency (antithrombin, protein C) 
state was diagnosed when functional plasma activity and immunological antigen 
concentration of a protein (analysis of protein C and protein S at least three months after the 
index event and/or withdrawal of vitamin-K-antagonists) were confirmed to be below the age-
related reference ranges.26-28, *1a and 1b A non-homozygous type II deficiency (antithrombin, 
protein C) was diagnosed when low functional activity levels were found along with normal 
antigen concentrations at least 3 months after the index event, repeated if abnormal.  The 
diagnosis of protein S deficiency was based on reduced free protein S antigen levels 
combined with decreased or normal total protein S antigen concentrations respectively at 
least 3 months after the index event, repeated if abnormal. Serum levels of Lp(a) > 30 mg/dl 
were considered elevated.15 Since data on normal values for fibrinogen and factor VIIIC in 
children are sparse, fibrinogen and factor VIIIC levels > age-dependent 90th percentiles, 
derived from the healthy control children were used as cut-off values. Criteria for the 
hereditary nature of a haemostatic defect were its presence in at least one further first or 
second-degree family member and/or the identification of a causative gene mutation.26-28 
 
*Reference values 1a and 1b 
 
 1a. Nowak-Göttl U, Limperger V, Kenet G, Degenhardt F, Arlt R, Domschikowski J, Clausnizer H, 
Liebsch J, Junker R, Steppat D. Developmental hemostasis: A lifespan from neonates and pregnancy 
to the young and elderly adult in a European white population. Blood Cells Mol Dis. 2017 Sep;67:2-13. 
doi:10.1016/j.bcmd.2016.11.012.  
 
1b. Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Münchow N, Assmann G, von Eckardstein A. 
Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. 
Circulation. 1999 Aug 17;100(7):743-748.  
 
Statistics: Patients with recurrent stroke were compared with patients without stroke 
recurrence. For the primary study objective, we calculated the symptomatic recurrence rate 
per 100 person-years and yearly incidence rates, based on the recruitment period and a 
median follow-up period of 35 months. Predictors possibly influencing symptomatic 
recurrence were defined a priori based on literature data and included stroke subtypes and 
prothrombotic risk factors (PR) significantly associated with a first AIS onset.11 Using a rule of 
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thumb for proportional hazards analysis including approximately 10 outcomes for each 
independent predictor,29 the final statistical model aimed to include seven predictors: 
calculated were the possible role of stroke subtypes on the recurrence rate per 100 person-
years and the possible influence of thrombophilic risk factors on recurrent AIS. In order to 
evaluate an independent contribution to the risk of recurrent AIS and to adjust for further 
potential confounders (age at onset, gender, study centre) the hazard ratio (HR) together 
with 95% confidence intervals (CI) were estimated from Cox’s proportional hazards model. 
Variables were removed from the backward model if p was > 0.16. Stroke groups (cardiac, 
vascular, non-cryptogenic/-cardiac,-vascular) were compared to cryptogenic stroke. Patients 
with no thrombophilia were compared with those with thrombophilia. Statistical analyses 
were performed using the MedCalc software bvba (version 16.4.3, Ostend, Belgium) and 
StatView 5 software packages (SAS Institute Inc.). The recurrence rates were calculated as 
the number of recurrent events per 100 person-years.  
 
For the secondary study objective, i.e. the time to recurrence, we calculated the probability of 
AIS-free survival (AFS) as a function of time utilizing the method of Kaplan and Meier 
(univariate analysis). The log rank test was used to test for differences in recurrence-free 
survival between groups. Patients were withdrawn from the survival analysis (censored 
cases) either at death unrelated to AIS recurrence or at loss to follow-up using data of the 
last clinical follow-up visit. To further test the relationship between independent and 
dependent variables, the likelihood ratio test was performed. Because of their apparently 
non-Gaussian distribution, continuous data are presented as median and minimum-
maximum (min.-max.) values and were evaluated by non-parametric statistics including the 
Wilcoxon-Mann-Whitney U test. To compare frequency distributions of fatal outcome, 2 test 
and, if necessary, Fisher’s exact test was performed. In addition, numbers needed to screen 
(NNS) were calculated as previously described.30 
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Results 
Figure 1 (supplement):  Stroke–free survival with respect to thrombophilia status 
(none versus combined) is depicted (p=0.039). 
 
 
 
